Fecal calprotectin levels are higher in rural than in urban Chinese infants and negatively associated with growth

BMC Pediatrics

K Michael Hambidge¹  Nancy F Krebs¹  Leland V Miller¹  Jamie E Westcott¹  Xiao-Gang Yu²  Yan-Qi Hu²  Xiao-Yang Sheng²  Jin-Rong Liu² 

[1] University of Colorado School of Medicine, Department of Pediatrics, Section of Nutrition, Box C225, Research Complex II, 12700 East 19th Avenue, Aurora, CO 80045, USA;Department of Child and Adolescent Health Care, MOE-Shanghai Key Laboratory of Children’s Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai Institute for Pediatric Research, 1665 Kongjiang Road, Shanghai, 200092, China

关键词: Growth;    Gut inflammation;    Children;    Infants;    Fecal calprotectin;   

Others  :  1170689
DOI  :  10.1186/1471-2431-12-129

 received in 2012-01-26, accepted in 2012-08-16,  发布年份 2012

【 摘 要 】

Background

Fecal calprotectin (FC) is an established simple biomarker of gut inflammation. To examine a possible relationship between linear growth and gut inflammation, we compared fecal calprotectin levels in 6 month old infants from poor rural vs affluent urban families.

Methods

The project was a cross-sectional comparison of FC from rural and urban populations in China. The relationship between length-for-age Z-score (LAZ) and FC concentrations were also compared. Single fecal samples were assayed for FC using EK-CAL ELISA kits.

Results

The age of subjects for both locations was 6.1 ± 0.2 mo; all were apparently healthy. The mean ± SD of the LAZ for the rural and urban infants were −0.6 ± 0.9 and 0.4 ± 0.9, respectively. FC had a non-normal distribution. The median FC of 420.9 and 140.1 μg/g for rural and urban infants, respectively, were significantly different (P < 0.0001). For the rural group, linear regression analysis showed that an increase in FC of 100 μg/g was associated with a decrease of 0.06 in LAZ.

Conclusion

FC levels were significantly elevated in the rural infants and high concentrations accounted for approximately one-third of the low LAZ scores of these infants.

【 授权许可】

   
2012 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Solomons NW, Mazariegos M, Brown KH, Klasing K: The underprivileged, developing country child: environmental contamination and growth failure revisited. Nutr Rev 1993, 51(11):327-332.
• [2]Campbell DI, Elia M, Lunn PG: Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation. J Nutr 2003, 133(5):1332-1338.
• [3]Panter-Brick C, Lunn PG, Goto R, Wright CM: Immunostimulation and growth faltering in UK infants. Am J Human Biol 2004, 16(5):581-587.
• [4]Campbell DI, McPhail G, Lunn PG, Elia M, Jeffries DJ: Intestinal inflammation measured by fecal neopterin in Gambian children with enteropathy: association with growth failure, Giardia lamblia, and intestinal permeability. J Pediatr Gastroenterol Nutr 2004, 39(2):153-157.
• [5]Lunn PG: The impact of infection and nutrition on gut function and growth in childhood. Proc Nutr Soc 2000, 59(1):147-154.
• [6]Goto R, Mascie-Taylor CG, Lunn PG: Impact of intestinal permeability, inflammation status and parasitic infections on infant growth faltering in rural Bangladesh. Brit J Nutr 2009, 101(10):1509-1516.
• [7]Panter-Brick C, Lunn PG, Langford RM, Maharjan M, Manandhar DS: Pathways leading to early growth faltering: an investigation into the importance of mucosal damage and immunostimulation in different socio-economic groups in Nepal. Brit J Nutr 2009, 101(4):558-567.
• [8]Dale I, Brandtzaeg P, Fagerhol MK, Scott H: Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am J Clin Pathol 1985, 84(1):24-34.
• [9]Roseth AG, Aadland E, Jahnsen J, Raknerud N: Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997, 58(2):176-180.
• [10]Roseth AG, Schmidt PN, Fagerhol MK: Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999, 34(1):50-54.
• [11]Gisbert JP, McNicholl AG, Gomollon F: Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis 2009, 15(11):1746-1754.
• [12]van Rheenen PF, Van de Vijver E, Fidler V: Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010, 341:c3369.
• [13]Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R: Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008, 40(7):547-553.
• [14]Berni Canani R, Rapacciuolo L, Romano MT, Tanturri De Horatio L, Terrin G, Manguso F, Cirillo P, Paparo F, Troncone R: Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Digestive Liver Dis 2004, 36(7):467-470.
• [15]Hanevik K, Hausken T, Morken MH, Strand EA, Morch K, Coll P, Helgeland L, Langeland N: Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection. J Infection 2007, 55(6):524-530.
• [16]Ton H, Brandsnes , Dale S, Holtlund J, Skuibina E, Schjonsby H, Johne B: Improved assay for fecal calprotectin. Clin Chim Acta 2000, 292(1–2)):41-54.
• [17]Ezri J, Nydegger A: [Pediatrics. Fecal calprotectin in children: use and interpretation]. Rev Med Suisse 2011, 7(277):69-70.
• [18]Hestvik E, Tumwine JK, Tylleskar T, Grahnquist L, Ndeezi G, Kaddu-Mulindwa DH, Aksnes L, Olafsdottir E: Faecal calprotectin concentrations in apparently healthy children aged 0–12 years in urban Kampala, Uganda: a community-based survey. BMC Pediatr 2011, 11:9. BioMed Central Full Text
• [19]Rugtveit J, Fagerhol MK: Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastroenterol Nutr 2002, 34(3):323-324. author reply 324–325
• [20]Hestvik E, Olafsdottir E, Tylleskar T, Aksnes L, Kaddu-Mulindwa D, Ndeezi G, Tumwine JK, Grahnquist L: Faecal calprotectin in HIV-infected, HAART-naive Ugandan children. J Pediatr Gastroenterol Nutr 2012, 54(6):785-790.
• [21]Campeotto F, Butel MJ, Kalach N, Derrieux S, Aubert-Jacquin C, Barbot L, Francoual C, Dupont C, Kapel N: High faecal calprotectin concentrations in newborn infants. Arch Dis Child Fetal Neonatal Ed 2004, 89(4):F353-F355.
• [22]Dorosko SM, Mackenzie T, Connor RI: Fecal calprotectin concentrations are higher in exclusively breastfed infants compared to those who are mixed-fed. Breastfeeding Med 2008, 3(2):117-119.
• [23]Olafsdottir E, Aksnes L, Fluge G, Berstad A: Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 2002, 91(1):45-50.
• [24]Savino F, Castagno E, Calabrese R, Viola S, Oggero R, Miniero R: High faecal calprotectin levels in healthy, exclusively breast-fed infants. Neonatology 2010, 97(4):299-304.
• [25]Nissen AC, van Gils CE, Menheere PP, Van den Neucker AM, van der Hoeven MA, Forget PP: Fecal calprotectin in healthy term and preterm infants. J Pediatr Gastroenterol Nutr 2004, 38(1):107-108.
• [26]Fagerberg UL, Loof L, Merzoug RD, Hansson LO, Finkel Y: Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr 2003, 37(4):468-472.
• [27]Kapel N, Campeotto F, Kalach N, Baldassare M, Butel MJ, Dupont C: Faecal calprotectin in term and preterm neonates. J Pediatr Gastroenterol Nutr 2010, 51(5):542-547.
• [28]Burri E, Beglinger C: Faecal calprotectin – a useful tool in the management of inflammatory bowel disease. Swiss Med Wkly 2012, 142:w13557.
• [29]van Rheenen PF: Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis 2012. [Epub ahead of print]
• [30]Fundaro C, Fantacci C, Ansuini V, Giorgio V, Filoni S, Barbaro F, Gasbarrini A, Rossi C: Fecal calprotectin concentration in children affected by SIBO. Eur Rev Med Pharmacol Sci 2011, 15(11):1328-1335.